Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tvardi TherapeuticsLTS:0HTC 8 3-1 Month Momentum % is N/A% as of Aug. 30, 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 1,385 Biotechnology companies, Tvardi Therapeutics ranks worse than 81.23% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-30), Tvardi Therapeutics's 3-1 Month Momentum % is N/A%.
The industry rank for Tvardi Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
LTS:0HTC's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -9.14 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Tvardi Therapeutics 3-1 Month Momentum % Related Terms
LTS:0HTC vs CRVO, JSPR, SKYE: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Tvardi Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tvardi Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Tvardi Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tvardi Therapeutics (LTS:0HTC) has a 3-1 Month Momentum % of N/A% as of Aug. 30, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Tvardi Therapeutics and its competitors. According to the industry distribution chart, Tvardi Therapeutics ranks #1125 out of 1385 companies in the Biotechnology industry, placing it in the top 81.2%.
Is Tvardi Therapeutics' 3-1 Month Momentum % too high?
Tvardi Therapeutics' current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Tvardi Therapeutics ranks #1125 out of 1385 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tvardi Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' 3-1 Month Momentum % compare to CRVO and JSPR?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #1125 out of 1385 companies for 3-1 Month Momentum %. This places Tvardi Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Tvardi Therapeutics' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current 3-1 Month Momentum % is N/A% as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
8GF Score
Get the complete analysis for LTS:0HTC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTC has been successfully added to your 
